Q32 Bio (QTTB) EBIAT (2017 - 2026)

Q32 Bio's EBIAT history runs 10 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• In Q1 2026, EBIAT rose 31.1% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at $33.2 million (up 155.56% YoY), while the FY2025 annual figure was $29.8 million, up 162.43% from the prior year.
• EBIAT was -$7.6 million for Q1 2026 at Q32 Bio, down from $57.7 million in the prior quarter.
• In the past five years, EBIAT ranged from a high of $92.1 million in Q1 2022 to a low of -$34.3 million in Q4 2022.
• Historically, EBIAT has averaged -$5.0 million across 5 years, with a median of -$11.0 million in 2025.
• The sharpest annual moves came in 2022 and 2025: EBIAT soared 8683.88% in 2022, then slumped 1172.01% in 2025.
• A 5-year view of EBIAT shows it stood at -$34.3 million in 2022, then advanced by 21.08% to -$27.1 million in 2023, then soared by 47.58% to -$14.2 million in 2024, then soared by 506.65% to $57.7 million in 2025, then tumbled by 113.17% to -$7.6 million in 2026.
• The last three EBIAT figures came in at -$7.6 million (Q1 2026), $57.7 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.